Esperion Therapeutics Provides ETC-1002 Development Program

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results

ANN ARBOR, MI --(Marketwired - November 05, 2015) - Esperion Therapeutics, Inc. ( NASDAQ : ESPR ), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided ETC-1002 (bempedoic acid) development program updates and financial results for the third quarter ended September 30, 2015.

"Our team remains focused and eager to advance the ETC-1002 development program into Phase 3 before year-end with the launch of our long-term safety study," said Tim M. Mayleben, president and chief executive officer of Esperion. "We look forward to providing an update on our full Phase 3 plans in the first half of 2016 as we continue to work with major global regulatory authorities and key opinion leaders on the potential worldwide approval of ETC-1002 for patients with hypercholesterolemia (elevated LDL-C levels), especially those patients with a history of statin intolerance."

Development Program and Company Highlights

  • July 28, 2015: Announced positive top-line results from the Phase 2 ETC-1002-014 clinical study in patients with both hypercholesterolemia and hypertension.
  • July 30, 2015: Hosted Second Annual Investor Day in New York City.
  • Early August: Held End-of-Phase 2 meeting with the FDA.
  • Late September: Announced updates from the final End-of-Phase 2 meeting minutes.

Upcoming Milestones

  • November 9, 2015: Two oral presentations at the American Heart Association (AHA) Scientific Sessions in Orlando FL:
    • "Identification of a Tissue Specific Very Long Chain Acyl-CoA Synthetase Involved in the Inhibition of ATP-Citrate Lyase (ACL) by ETC-1002: A Novel Mechanism for Cholesterol Biosynthesis Inhibition in the Liver," presented by Stephen Pinkosky, Sr. Scientist, Head of Translational Research, Esperion Therapeutics, at 11:45am in Room W303;
    • "ETC-1002 Incrementally Lowers Low Density Lipoprotein Cholesterol in Patients with Hypercholesterolemia Receiving Stable Statin Therapy," presented by Christie Ballantyne MD, Baylor College of Medicine, at 6:30pm in Room W205.
  • November 10, 2015: Presentation and webcast of full results of the Phase 2b ETC-1002-009 clinical study and new data on ATP Citrate Lyase inhibition, the mechanism of action of LDL-C lowering for ETC-1002.
  • December 2015:
    • Initiation of the Phase 2 ETC-1002-035 clinical study evaluating ETC-1002 in combination with high-dose statins (HDS);
    • Initiation of the Phase 3 ETC-1002-040 long-term safety study evaluating ETC-1002 compared to placebo in patients on background statin therapy.
  • 1H 2016:
    • File Investigational New Drug Application (IND) for the fixed dose combination of ETC-1002 and ezetimibe;
    • Announce Phase 3 worldwide development plans for ETC-1002.
  • Mid-2016:
    • Announce top-line results from the Phase 2 ETC-1002-035 clinical study evaluating ETC-1002 in combination with high-dose statins (HDS);
    • Initiation of the Phase 3 efficacy study of ETC-1002 in patients with statin intolerance.
  • 2H 2016:
    • Initiation of the Phase 3 cardiovascular outcomes study for ETC-1002.

2015 Third Quarter Financial Results

As of September 30, 2015, cash and cash equivalents and investment securities available-for-sale totaled $302.4 million compared with $141.6 million at December 31, 2014.

Research and development expenses were $7.2 million for the third quarter of 2015 and $21.8 million for the nine months ended September 30, 2015, compared to $7.2 million and $19.1 million for the comparable periods in 2014. The increase in research and development expenses was primarily related to the further clinical development of ETC-1002.

General and administrative expenses were $5.7 million for the third quarter of 2015 and $15.0 million for the nine months ended September 30, 2015, compared to $2.5 million and $7.7 million for the comparable periods in 2014. The increase in general and administrative expenses was primarily attributable to costs to support public company operations, increases in headcount, which includes increased stock-based compensation expense, and other costs to support Esperion's growth.

Esperion had a net loss of $12.8 million for the third quarter of 2015 and $36.7 million for the nine months ended September 30, 2015, compared to $9.8 million and $26.9 million for the comparable periods in 2014.

Esperion had approximately 22.5 million shares of common stock outstanding, with an additional 2.9 million shares issuable upon exercise of stock options and warrants and vesting of restricted stock, and $4.7 million of debt outstanding as of September 30, 2015.

2015 Financial Outlook

Esperion expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities available-for-sale will total approximately $290 million at December 31, 2015. The Company estimates that current cash resources are sufficient to fund the Company through at least the end of 2018 and the potential approval of ETC-1002.

Conference Call and Webcast Information

Esperion's management team will not host a conference call to review financial results from the third quarter ended September 30, 2015. Esperion will hold a live webcast briefing on Tuesday, November 10, 2015 at 7:45 a.m. Eastern Time to provide full clinical results of the Phase 2b ETC-1002-009 study and new data on ATP Citrate Lyase inhibition, the mechanism of action for LDL-C lowering for ETC-1002. Please visit www.esperion.com for webcast access and dial-in details.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company's lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc .

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of, and clinical development plan for, ETC-1002 and the fixed-dose combination of ETC-1002 and ezetimibe. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that FDA may require additional studies or data, including prior to approval that might cause approval to be delayed, that Esperion may need to change the design of its Phase 3 program, including upon feedback from regulatory authorities, that positive results from a clinical study of ETC-1002 and the fixed-dose combination of ETC-1002 and ezetimibe may not necessarily be predictive of the results of future clinical studies, particularly in different or larger patient populations, or in all statin doses, including high doses, or the risk that other unanticipated developments or data could interfere with the scope of development and commercialization of ETC-1002 and the fixed-dose combination of ETC-1002 and ezetimibe, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

   
   
Esperion Therapeutics, Inc.  
             
Balance Sheet Data  
(In thousands)  
(Unaudited)  
             
September 30,     December 31,  
2015     2014  
Cash and cash equivalents   $ 80,824     $ 85,038  
Working capital     212,017       101,208  
Investments     221,543       56,544  
Total assets     306,394       143,276  
Total long-term debt     3,084       4,231  
Common stock     23       20  
Accumulated deficit     (141,100 )     (104,438 )
Total stockholders' equity     296,482       133,554  
                 
                 
Esperion Therapeutics, Inc.  
                   
Statement of Operations  
(In thousands, except share and per share data)  
(Unaudited)  
           
    Three Months Ended September 30,   Nine Months Ended September 30,  
    2015   2014   2015   2014  
Operating expenses:                          
  Research and development   $ 7,247   $ 7,174   $ 21,846   $ 19,102  
  General and administrative     5,672     2,526     14,960     7,742  
Total operating expenses     12,919     9,700     36,806     26,844  
Loss from operations     (12,919 )   (9,700 )   (36,806 )   (26,844 )
                           
Interest expense     (130 )   (135 )   (399 )   (136 )
Other income, net     248     29     543     62  
Net loss   $ (12,801 ) $ (9,806 ) $ (36,662 ) $ (26,918 )
Net loss per common share (basic and diluted)   $ (0.57 ) $ (0.64 ) $ (1.68 ) $ (1.75 )
Weighted average shares outstanding (basic and diluted)     22,494,075     15,432,641     21,854,685     15,397,745  

Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 104

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Mission Rock Takes Charge of Seasons at Horsetooth

Updated Category News Views 20

Mission Rock Shakes Up Colorado's Apartment Market Here's one for the books: Mission Rock Residential, known for its no-nonsense approach to property management, just snagged a juicy piece of the market by taking over management at Seasons at Horsetooth Crossing in Fort Collins. Fort Collins isn't just some random name on the map—it's a hotbed for real estate, thanks to...

Continue Reading
Teck Resources Confirms Quarterly Dividend for Shareholders

Updated Category News Views 175

Teck Resources Declares New Dividend for Shareholders Teck Resources Limited (NYSE: TECK) has made an exciting announcement that will please its investors. The company has declared a quarterly dividend of $0.125 per share designated for its outstanding Class A common shares and Class B subordinate voting shares. This dividend is set to be paid on March 31 to all...

Continue Reading
Empowering Voices: The Impact of the AWDPI Conference

Updated Category News Views 300

Empowering Women Through Innovative Discussions The recent conference organized by the Asian Women Development Plan International brought together over 10,000 individuals passionate about empowering Asian women. This pivotal gathering, titled "The Conference of Asian Women Development International 2024", served as a beacon for women's issues, fostering a collaborative...

Continue Reading
O2Gold Shares Significant Updates on Quebec Aur Acquisition

Updated Category News Views 205

O2Gold's Exciting Update on Quebec Aur Acquisition O2Gold Inc. (NEX:OTGO.H), a dynamic player in the mineral exploration landscape, is thrilled to provide an update on its ongoing journey towards acquiring a gold mining exploration property in Quebec. This acquisition is through the purchase of Quebec Aur Ltd., with the transaction details specified in a share exchange...

Continue Reading
Skycorp Solar Group Limited Announces Major IPO Initiative

Updated Category News Views 187

Skycorp Solar Group Limited Announces Major IPO Initiative Skycorp Solar Group Limited (PN) has made a notable move by filing for an initial public offering (IPO) that encompasses 2,000,000 shares. The pricing is positioned attractively between $4 and $5 per share, appealing to a diverse range of potential investors. Understanding the IPO Process An IPO is a crucial step...

Continue Reading